At the heart of the case is the language of the 340B program statute itself.

Arnold & Porter Kaye Scholer attorney Allon Kedem argued during a Monday hearing that the wording allows AstraZeneca to limit when it offers discounted prices. But U.S. Department of Justice attorney Kate Talmor said the company’s focus on how the law’s wording should be interpreted is a strategy for AstraZeneca to divert attention from its Congressionally intended general purpose of providing drug discounts to covered entities.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]